BioSpace News Archive

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its second quarter 2021 earnings results on Wednesday, July 28, 2021, after the close of the market.

Integra LifeSciences Holding Corporation, a leading global medical technology company, announced its SurgiMend® Collagen Matrix for Soft Tissue Reconstruction has received an Innovative Technology contract from Vizient, Inc. the nation’s largest member-driven health care performance improvement company.

Taro Pharmaceutical Industries Ltd. announced that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021.

Acutus Medical, Inc. announced the pricing of its underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $14.00 per share.

The laboratory balances and scales market is expected to reach US$ 2,131.14 million in 2028 from US$ 1,463.53 million in 2021. The market is estimated to grow with a CAGR of 5.5% from 2021-2028.

The pharmacovigilance and drug safety software market is expected to reach US$ 292.97 Mn in 2027 from US$ 160.67 Mn in 2019. The market is estimated to grow with a CAGR of 7.6% from 2020-2027.

Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biotechnology company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases with unmet medical needs, has initiated activities for a Phase 2 international clinical study for the treatment of patients with multiple sclerosis (MS).

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), is pleased to announce interim positive results from its ongoing preclinical study evaluating the Company’s patented enteric-coated formulation of Cepharanthine (“PD-001") in a broad panel of human cancers.

CohBar, Inc. today announced an update on the timing for the release of the data for its Phase 1a/1b clinical study of CB4211 for the potential treatment of nonalcoholic steatohepatitis and obesity.

Evvy, a female-founded startup that aims to build a new understanding of the female body, launches today